MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibitionRebecca C. Coll, Kate Schroder|Nature Chemical Biology|2019Cited by 975
The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 InflammasomesRebecca C. Coll, Luke O'neill|PLoS ONE|2011Cited by 136
NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasomeJ. Coombs, Kate Schroder, Caroline L. Holley et al.|Science Signaling|2024Cited by 40
Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of actionKevin Wilhelmsen, Rebecca C. Coll|The Journal of Experimental Medicine|2025Cited by 11
Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 InflammasomesRebecca C. Coll, Luke O'neill|PLoS ONE|2013Cited by 0